0.0016USD+725.00%Mkt Cap: 73547 USDP/E: —Last update: 2026-05-22
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product can…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap73.55K USD
Enterprise Value4.81M USD
Revenue (TTM)22.36M USD
Gross Profit5.21M USD
Net Income (TTM)-30.37M USD
Revenue/Share0.6950 USD
Last Price0.0016 USD
Fiscal Year EndDec 2022
MR QuarterSep 2023
Employees37
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA-13.87
EV/Revenue0.22
P/S0.00
P/B-0.00
EPS (TTM)-0.02
EPS (Forward)-0.09
52W Range
0.00013% of range0.0500
52W High0.0500 USD
52W Low0.0001 USD
Profitability
Gross Margin23.28%
Oper. Margin-208.39%
EBITDA Margin-1.55%
Profit Margin-5.11%
ROE125.33%
ROA-206.68%
Growth
Revenue Growth4.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.13M USD
CapEx (TTM)82.00K USD
FCF Margin-73.28%
FCF Yield-22278.27%
Net Debt4.80M USD
Net Debt/EBITDA-13.85
Balance Sheet
Debt/Equity-0.25
Current Ratio0.23
Quick Ratio0.03
Book Value/Sh-0.2650 USD
Cash/Share0.0010 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.44.57M
Float40.31M
Insiders0.00%
Institutions11.44%
Short Interest
Short Ratio0.2d
Short % Float6.80%
Short % Out.5.55%
Shares Short2.00M
Short (prev mo.)439.68K
Technical
SMA 500.0004 (+299.5%)
SMA 2000.0006 (+186.1%)
Beta3599.34
S&P 52W Chg28.31%
Avg Vol (30d)9.96K
Avg Vol (10d)17.60K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—